|
Remicade (infliximab) is used for reducing signs and symptoms of moderate to severe rheumatoid arthritis when used along with another medicine (methotrexate). It is also used to reduce symptoms of moderate to severe ankylosing spondylitis, psoriatic arthritis, and certain types of skin psoriasis. Remicade is used to reduce symptoms of moderate to severe Crohn disease or ulcerative colitis in patients who have not received relief from other treatments.
Remicade dosage for Rheumatoid Arthritis
The recommended dose of Remicade is 3 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. Remicade should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks.
Remicade dosage for Crohn’s Disease or Fistulizing Crohn’s Disease
The recommended dose of (infliximab) is 5 mg/kg given as an induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active Crohn’s disease or fistulizing disease. For patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue Remicade in these patients.
|
